| Indicators | Browse All

Definium Therapeutics, Inc. (DFTX)

Healthcare | Biotechnology | New York, United States | NasdaqGS
43.65 USD -3.42 (-7.266%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 44.00 +0.35 (0.802%) ⇧ (July 13, 2026, 7:52 p.m. EDT)

Short-term:★★★★☆Long-term:★★★☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:20 a.m. EDT

The narrative here is a classic biotech turnaround story fueled by a massive Phase 3 win and a fresh capital raise. While the company is burning cash and lacks profitability, the balance sheet is surprisingly robust with minimal debt and ample cash reserves, allowing them to weather the storm while waiting for commercialization. The recent price surge and the $805 million offering suggest the market is pricing in a successful path to approval and eventual revenue. However, the statistical forecasting model is completely useless here, showing very low confidence and zero predictive power, which is typical for event-driven biotech stocks where binary outcomes dominate price action. The options market is screaming for upside, betting on a continuation of the rally toward $60, while the fundamental reality remains that this is still a high-risk venture with no guaranteed product launch date.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.106693
MSTL0.108456
AutoTheta0.128909
AutoARIMA0.177947

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 18%
H-stat 28.18
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 3.92
Attribute Value
Sector Healthcare
Debt to Equity Ratio 14.622
Market Cap 5,794,243,072
Forward P/E -28.89
Beta 2.21
Previous Name Mind Medicine (MindMed) Inc.
Website https://definiumtx.com

As of July 11, 2026, 4:20 a.m. EDT: Speculators are aggressively positioning for a breakout above the $47-$50 resistance zone. Call volume spikes significantly at strikes $50, $55, and $60, with the $60 strike showing massive new inflow relative to open interest, suggesting a bet on a rapid move to $60+. Conversely, put activity is concentrated deep in-the-money (below $20) and at the immediate support level ($45-$47), indicating a 'floor' defense strategy rather than a bearish crash thesis. Implied volatility remains elevated across the board, reflecting uncertainty around the upcoming catalysts.


Info Dump

Attribute Value
52 Week Change 4.65066
Address1 One World Trade Center
Address2 Suite 8500
All Time High 86.55
All Time Low 0.015
Ask 56.11
Ask Size 2
Audit Risk 7
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 3,954,030
Average Daily Volume3 Month 2,937,981
Average Volume 2,937,981
Average Volume10Days 3,954,030
Beta 2.212
Bid 32.65
Bid Size 2
Board Risk 3
Book Value 2.68
City New York
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 43.65
Current Ratio 4.692
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 46.41
Day Low 43.38
Debt To Equity 14.622
Display Name Definium Therapeutics
Earnings Call Timestamp End 1,778,185,800
Earnings Call Timestamp Start 1,778,185,800
Earnings Timestamp 1,778,184,000
Earnings Timestamp End 1,785,441,600
Earnings Timestamp Start 1,785,441,600
Ebitda Margins 0.0
Enterprise Value 4,428,115,968
Eps Current Year -2.2325
Eps Forward -1.51091
Eps Trailing Twelve Months -2.5
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 28.67
Fifty Day Average Change 14.980001
Fifty Day Average Change Percent 0.5224974
Fifty Two Week Change Percent 465.066
Fifty Two Week High 49.2
Fifty Two Week High Change -5.549999
Fifty Two Week High Change Percent -0.11280486
Fifty Two Week Low 7.96
Fifty Two Week Low Change 35.690002
Fifty Two Week Low Change Percent 4.483669
Fifty Two Week Range 7.96 - 49.2
Financial Currency USD
First Trade Date Milliseconds 1,479,220,200,000
Float Shares 107,083,949
Forward Eps -1.51091
Forward P E -28.889875
Free Cashflow -45,625,376
Full Exchange Name NasdaqGS
Full Time Employees 105
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.013300001
Held Percent Institutions 0.65834
Implied Shares Outstanding 132,743,254
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,661,731,200
Last Split Factor 1:15
Long Business Summary Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Long Name Definium Therapeutics, Inc.
Market us_market
Market Cap 5,794,243,072
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_631045282
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -237,543,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 6,248,224,965
Number Of Analyst Opinions 15
Open 46.0
Operating Cashflow -144,772,000
Operating Margins 0.0
Overall Risk 4
Payout Ratio 0.0
Phone 212 220 6633
Post Market Change 0.34999847
Post Market Change Percent 0.8018292
Post Market Price 44.0
Post Market Time 1,783,986,733
Prev Name Mind Medicine (MindMed) Inc.
Previous Close 47.07
Price Eps Current Year -19.552073
Price Hint 2
Price To Book 16.287313
Profit Margins 0.0
Quick Ratio 4.604
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.26667
Region US
Regular Market Change -3.42
Regular Market Change Percent -7.26577
Regular Market Day High 46.41
Regular Market Day Low 43.38
Regular Market Day Range 43.38 - 46.41
Regular Market Open 46.0
Regular Market Previous Close 47.07
Regular Market Price 43.65
Regular Market Time 1,783,972,801
Regular Market Volume 1,806,875
Return On Assets -0.35724
Return On Equity -0.94704
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 2
Shares Outstanding 132,743,254
Shares Percent Shares Out 0.1094
Shares Short 14,517,267
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 9,425,925
Short Name Definium Therapeutics, Inc.
Short Percent Of Float 0.1101
Short Ratio 3.05
Source Interval 15
State NY
Symbol DFTX
Target High Price 74.0
Target Low Price 48.0
Target Mean Price 57.8
Target Median Price 57.0
Total Cash 373,422,016
Total Cash Per Share 3.424
Total Debt 40,773,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.5
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 18.70255
Two Hundred Day Average Change 24.94745
Two Hundred Day Average Change Percent 1.3339063
Type Disp Equity
Volume 1,806,875
Website https://definiumtx.com
Zip 10,007